Vimian Group reports 7% miss in Q2 adjusted EBITA

Investing.com -- Vimian Group AB (STO:VIMIAN) reported second-quarter results below expectations, with adjusted EBITA of EUR 25.4 million, missing analyst consensus by 7%.

The animal health company posted net sales of EUR 104.3 million, up 15% year-over-year but 2% below Modular Finance consensus estimates.

The revenue miss was primarily due to weaker-than-expected performance in the Specialty Pharma and MedTech segments.

Adjusted EBITA grew 3% year-over-year, with margins contracting to 24.3% from 27.2% in the same period last year. Analysts had expected a margin of 25.4%.

The company achieved 5% organic growth at the group level, with Specialty Pharma growing 6%, Veterinary Services 12%, and Diagnostics 18%.

These gains were partially offset by a 4% organic decline in MedTech, which the company attributed to a continued soft US surgery market.

By segment, Specialty Pharma generated EUR 45.3 million in revenue (+4% year-over-year) with an adjusted EBITA margin of 30.0%, slightly up from 29.7% last year.

MedTech revenue reached EUR 37.1 million (+32% year-over-year), but its adjusted EBITA margin fell significantly to 23.7% from 31.6% in the second quarter of 2024.

Veterinary Services posted EUR 16.2 million in revenue (+12% year-over-year) with an improved margin of 28.7%, up from 27.6%.

The Diagnostics segment generated EUR 5.7 million (+16% year-over-year) with a margin of 9.2%, compared to 8.2% in the prior year period.

In a separate development, Vimian announced the departure of its CEO, with CFO Carl-Johan Zetterberg Boudrie appointed as interim CEO.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Should you invest $2,000 in VIMIAN right now?

With VIMIAN making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed VIMIAN alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including VIMIAN, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is VIMIAN poised for similar growth? Don't miss the opportunity to find out.

Reveal Undervalued Stocks Now